Skip to main content
    P

    ProKidney Corp. (PROK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.04
    -0.01 (-0.48%)

    Market Cap: $417.20M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    ProKidney Corp. (PROK) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect ProKidney (PROK) to earn -$0.58 per share in the fiscal year ending Dec 31, 2026, on revenue of $634800. Of 6 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.67, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 67% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy466.7%
    Hold116.7%
    Sell00.0%
    Strong Sell116.7%
    Consensus
    Hold
    Total analysts
    6

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 2.7%.

    Fiscal year ending Dec 31, 2026
    -$0.58
    EPS consensus, revenue $634800
    Fiscal year ending Dec 31, 2027
    -$0.76
    EPS consensus, revenue $617750
    Next report
    Mar 16, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.58-$0.66 to -$0.514$634800$376000 to $8000005
    Dec 31, 2027-$0.76-$1.35 to -$0.425$617750$495000 to $8000004

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.14-$0.19 to -$0.128$136068N/A8

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 1 upward and 8 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202605
    Fiscal year ending Dec 31, 202713

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.56.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.58-$0.58-$0.56-$0.56-$0.56N/A
    Fiscal year ending Dec 31, 2027-$0.76-$0.61-$0.59-$0.59-$0.59N/A

    Frequently Asked Questions About PROK

    What is the PROK stock forecast?

    Consensus analyst estimates put ProKidney's EPS at -$0.58 for the fiscal year ending Dec 31, 2026, on revenue of $634800. The consensus rating from 6 analysts is Hold.

    How do analysts rate PROK stock?

    Of 6 analysts covering ProKidney, 0 rate it Strong Buy, 4 Buy, 1 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from PROK next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.58, with estimates from -$0.66 to -$0.51 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.76, with estimates from -$1.35 to -$0.42 from 5 analysts.

    What revenue do analysts expect from ProKidney next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $634800, with estimates from $376000 to $800000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $617750, with estimates from $495000 to $800000.

    How many analysts cover PROK?

    6 analysts rate ProKidney stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.